Health News Releases

  • Today December 20
November 06, 2018 13:30
OptraSCAN® Unveils High-Speed, High-Throughput, High-Capacity and High-Content “Multi-Modality Digital Slide Scanner”
OptraSCAN®, the leading On-Demand Digital Pathology solution provider, today unveiled a new Multi-Modality Digital Slide Scanner, with features such as high-speed, high-throughput, high-capacity and h
November 06, 2018 10:35
Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Initial effectiveness results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study showed empagliflozin was associated with a 44 percent relative risk reduction in ho
November 06, 2018 09:00
Aurigene to Present Multiple Programs at the SITC 2018 in Washington D.C. and EORTC-NCI-AACR 2018 in Dublin
Aurigene: SITC - Nov 7-11, Washington D.C.: (a) CA-170 - Small molecule oral antagonist of PD-L1/VISTA in Ph-2 (India) (b) Small molecule oral antagonist of CD47 (c) Small molecule oral antago
November 05, 2018 10:30
Takeda to Present Data During 60th American Society of Hematology Annual Meeting on Wide Array of Treatment Needs for Blood Cancers
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it will present a total of 18 company-sponsored abstracts at the 60th American Society of Hematology (ASH) Annual Meeting taking
November 01, 2018 14:20
Galderma, Nestlé Skin Health’s Medical Solutions Business, Announces Positive Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Galderma, Nestlé Skin Health’s medical solutions business, today announced positive results from a Phase 2b dose-ranging study of nemolizumab in adult patients with moderate-to-severe atopic dermatiti
November 01, 2018 14:15
Takeda Reports Second Quarter FY2018 Results
Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue +4.2%, led by Growth Drivers, with growth in every region · Underlying Revenue was solid at +4.2%, with continued strong mo
October 31, 2018 18:35
Ferring Announces Retirement of Michel Pettigrew, President of the Executive Board and Chief Operating Officer
Ferring Pharmaceuticals today announced that Michel Pettigrew, President of the Executive Board and Chief Operating Officer, will retire from his operational activities effective December 31, 2018. Pe
October 31, 2018 15:25
Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancer
Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs to treat NASH and cancer, today announced the clos
October 31, 2018 11:35
Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA®▼ (D/C/F/TAF) in Treatment-Naïve Adults with HIV-1
The Janssen Pharmaceutical Companies of Johnson & Johnson today unveiled 96-week results from the pivotal Phase 3 AMBER study of SYMTUZA® (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and
October 29, 2018 13:25
Takeda Comments on Ongoing Phase 1 Review by the European Commission of the Proposed Acquisition of Shire plc
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today issued the following statement with regard to its discussions with the European Commission (“EC”) as part of its Phase 1 review of th
October 29, 2018 10:50
Takeda Announces Execution of Senior Short Term Loan Facility Agreement and Subordinated Syndicated Loan Agreement and Second Amendment to Bridge Credit Agreement in Connection with Proposed Acquisition of Shire plc
Takeda Pharmaceutical Company Limited (TSE:4502) (the “Company or “Takeda”) announces that it has today entered into a Senior Short Term Loan Facility Agreement (the “SSTL”) for an aggregate principal
October 26, 2018 15:40
Takeda to Highlight Data in Hodgkin Lymphoma During the 11th International Symposium on Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the company will feature a total of six company-sponsored abstracts, including two oral presentations, at the 11th International
October 25, 2018 17:15
Eminent Scientist James Till Turned Philanthropist; Donates Prize Money to the Cause of Young Researchers
Stem cell discoverer Prof. James Till, Professor Emeritus, University of Toronto, Canada who was awarded the Edogawa Niche Prize 2018 (www.edogawanicheprize.org), jointly by Nichi-In Centre for Regene
October 25, 2018 13:45
Morinaga Milk Study Suggests Infant-Type Human-Residential Bifidobacteria May Benefit Infant Health by Improving Digestion of Peptides in Milk and Grains
Scientists at Morinaga Milk Industry Co., Ltd. (TOKYO:2264) have long theorized that Human-Residential Bifidobacteria (HRB) are superior to non-Human-Residential Bifidobacteria (non-HRB) in promoting
October 23, 2018 14:00
ResMed Wins German Patent Infringement Case Against Fisher & Paykel
ResMed (NYSE: RMD) (ASX: RMD), the world’s leading tech-driven medical company and innovator in sleep apnea and respiratory care, today announced the results of a court and patent office ruling in Ger
October 22, 2018 18:00
Outline of New ESMO Guidelines Indicates Inclusion of FOTIVDA®▼ (Tivozanib) for Patients with Advanced Renal Cell Carcinoma
EUSA Pharma (EUSA) welcomes the news that FOTIVDA®▼ (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology (ESMO) clinical practice guidelines for advanced renal c
October 22, 2018 17:15
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved in
October 22, 2018 16:50
Edogawa Niche Prize 2018 to Be Awarded to Prof. James Till for Stem Cell Discovery
The Edogawa Niche Prize 2018, jointly established by Nichi-In Centre for Regenerative Medicine (NCRM) and Edogawa Hospital, Tokyo, Japan will be awarded to Prof. James Till, Professor Emeritus, Univer
October 22, 2018 14:25
Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC)
October 22, 2018 14:10
Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC
Boehringer Ingelheim today announced results from GioTag, a real-world retrospective study which examined the impact of first-line Giotrif®/Gilotrif® (afatinib) followed by osimertinib, in epidermal g
October 19, 2018 13:45
Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
October 17, 2018 17:40
Ferring and Evotec Form Strategic Research Alliance in Reproductive Medicine and Women’s Health
Ferring Pharmaceuticals and Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a strategic research alliance to discover and develop new small molecule therapie
October 17, 2018 15:35
Brightree Launches First Patient App for HME
Brightree®, the leading provider of cloud-based software to help post-acute care companies improve business performance and patient outcomes, announced today from Medtrade the release of its new Patie
October 17, 2018 11:00
AirFit F30, ResMed’s First Minimal-Contact Full Face CPAP Mask, Now Available in the U.S., Canada
ResMed (NYSE: RMD, ASX: RMD) today announced the availability of its first minimal-contact full face CPAP mask, AirFit F30, the latest addition to its AirFit mask portfolio, which helps sleep apnea pa
October 15, 2018 16:30
Results from Pradaxa® RE-SPECT ESUS® and RE-SPECT CVT® trials to be presented at the 11th World Stroke Congress
Boehringer Ingelheim today announced that primary results from two key trials, RE-SPECT ESUS® and RE-SPECT CVT®, will be presented at the upcoming World Stroke Congress in Montreal, Canada 17-20 Octob
25 per page50 per page75 per page100 per page